1H-pyrazolo[3,4-

1. A compound or pharmaceutically acceptable salt or prodrug thereof having the structure of formula Ib:

wherein:

R 1 , R 2 , R 3 , R 5 , R 6 , and R 8 are independently selected from the group consisting of H, C 1-9 alkyl, halide, —CF 3 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 , —(C 1-9 alkyl) n heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n N(R 9 )C(=A)CH(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

one of each R 1 and R 2 , R 2 and R 3 , or R 5 and R 6 are taken together to form a ring which is selected from the group consisting of aryl, heteroaryl,

wherein each bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond;

each R 9 is independently selected from the group consisting of H, C 1-9 alkyl, —CF 3 , —(C 1-9 alkyl) n carbocyclyl, —(C 1-9 alkyl) n heterocyclyl, —(C 1-9 alkyl) n aryl and —(C 1-9 alkyl) n heteroaryl;

alternatively, two adjacent R 9 , may be taken together with the atoms to which they are attached to form a carbocyclyl or heterocyclyl;

each R 10 is independently selected from the group consisting of C 1-9 alkyl, —CF 3 , —(C 1-9 alkyl) n carbocyclyl, —(C 1-9 alkyl) n heterocyclyl, —(C 1-9 alkyl) n aryl and —(C 1-9 alkyl) n heteroaryl;

each R 11 is independently selected from the group consisting of —OR 9 and R 9 ;

each R 12 is 1-5 substituents each selected from the group consisting of H, C 1-9 alkyl, halide, —CF 3 , carbocyclyl, heterocyclyl, aryl, heteroaryl, —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 )SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n N(R 9 )C(=A)CH(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

R 14 and R 15 are independently selected from the group consisting of H, C 1-9 alkyl, halide, —CF 3 , —(C 1-9 alkyl) n carbocyclylR 12 , —(C 1-9 alkyl) n heterocyclylR 12 , —(C 1-9 alkyl) n arylR 12 , —(C 1-9 alkyl) n heteroarylR 12 , —(C 1-9 alkyl) n OR 9 , —(C 1-9 alkyl) n SR 9 , —(C 1-9 alkyl) n S(═O)R 10 , —(C 1-9 alkyl) n SO 2 R 9 , —(C 1-9 alkyl) n N(R 9 ) n SO 2 R 9 , —(C 1-9 alkyl) n SO 2 N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n C(=A)N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , —(C 1-9 alkyl) n N(R 9 )C(=A)CH(R 9 ) 2 , —NO 2 , —CN, —(C 1-9 alkyl) n CO 2 R 9 and —(C 1-9 alkyl) n C(=A)R 9 ;

alternatively, R 14 and R 15 are taken together to form a ring which is selected from the group consisting of benzene and pyridine;

each A is independently selected from O, S and NR 11 ;

Y 1 , Y 2 and Y 4 are carbon;

Y 3 is nitrogen;

R 7 is absent; and

each n is 0 or 1.

2. The compound of claim 1 wherein n is 0.

3. The compound of claim 1 wherein n is 1.

4. The compound of claim 1 wherein A is O.

5. The compound of claim 1 wherein R 1 and R 3 are H and R 2 is selected from the group consisting of -carbocyclylR 12 , -heterocyclylR 12 , -arylR 12 and -heteroarylR 12 .

6. The compound of claim 5 wherein R 2 is -heteroarylR 12 .

7. The compound of claim 6 wherein the heteroaryl is pyridine.

8. The compound of claim 6 wherein R 12 is selected from the group consisting of —NHC(═O)N(R 9 ) 2 , —C(═O)N(R 9 ) 2 , —NHC(═O)R 9 , —NHC(═O)CH(R 9 ) 2 and —NHSO 2 R 9 .

9. The compound of claim 8 wherein R 9 is selected from the group consisting of H, —C 1-4 alkyl, carbocyclyl and -heterocyclyl.

10. The compound of claim 1 wherein R 6 and R 8 are H and R 5 is selected from the group consisting of H, -heterocyclylR 12 , -arylR 12 , -heteroarylR 12 , —N(R 9 )C(═O)N(R 9 ) 2 , —C(═O)N(R 9 ) 2 , —N(R 9 )C(═O)R 9 , —N(R 9 )C(═O)CH(R 9 ) 2 , —CN, —CO 2 R 9 and —C(═O)R 9 .

11. The compound of claim 10 wherein R 5 is selected from the group consisting of -heterocyclylR 12 , -arylR 12 and -heteroarylR 12 .

12. The compound of claim 11 wherein R 12 is selected from the group consisting of H and halide.

13. The compound of claim 11 wherein the heteroaryl is pyridine.

14. The compound of claim 10 wherein R 5 is selected from the group consisting of H, —C(═O)N(R 9 ) 2 and —CN.

15. The compound of claim 14 wherein R 9 is selected from the group consisting of H and —C 1-4 alkyl, alternatively, R 9 is taken together to form a fused ring with the nitrogen.

16. The compound of claim 1 having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a therapeutically effective amount of compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

18. The compound of claim 1 , wherein R 1 , R 3 , R 6 , and R 8 are H; Y 3 is nitrogen; R 7 is absent; R 2 is heteroarylR 12 , R 5 is arylR 12 .

19. The compound of claim 18 , wherein R 5 is selected from the group consisting of:

20. The compound of claim 19 , wherein R 2 is pyridineR 12 and R 12 is selected from the group consisting of —(C 1-9 alkyl) n N(R 9 ) 2 , —(C 1-9 alkyl) n N(R 9 )C(=A)N(R 9 ) 2 , and —(C 1-9 alkyl) n N(R 9 )C(=A)R 9 , R 9 is selected from a group consisting of H and C 1-9 alkyl; and A is O.

21. The compound of claim 20 , wherein R 5 is selected from the group consisting of:

22. The compound of claim 1 having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.